Cargando…

The association between soluble CD163, disease severity, and ursodiol treatment in patients with primary biliary cholangitis

The macrophage activation marker soluble (s)CD163 is associated with disease severity and prognosis in patients with primary biliary cholangitis (PBC). Ursodeoxycholic acid (UDCA) treatment attenuates fibrosis progression in PBC patients, but its effect on macrophage activation is unclear. We examin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bossen, Lars, Lau, Tobias Stemann, Nielsen, Mette Bak, Nielsen, Marlene Christina, Andersen, Astrid Højmark, Ott, Peter, Becker, Sabine, Glerup, Henning, Svenningsen, Lise, Eivindson, Martin, Kornerup, Linda, Kjeldsen, Niels Bjørndal, Neumann, Anders, Møller, Holger Jon, Jepsen, Peter, Grønbæk, Henning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043550/ https://www.ncbi.nlm.nih.gov/pubmed/36972379 http://dx.doi.org/10.1097/HC9.0000000000000068

Ejemplares similares

Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure
por: Nielsen, Marlene Christina, et al.
Publicado: (2020)

Immediate hypersensitivity reaction followed by successful oral desensitization to ursodiol
por: Lee, Erika Yue, et al.
Publicado: (2021)

Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis
por: Bossen, Lars, et al.
Publicado: (2021)

Contacts to general practice in the 12 months preceding a diagnosis of an abdominal cancer: a national register-based cohort study
por: Jessen, Nanna Holt, et al.
Publicado: (2022)

Soluble CD163 correlates with lipid metabolic adaptations in type 1 diabetes patients during ketoacidosis
por: Svart, Mads, et al.
Publicado: (2018)

No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial
por: Kimer, Nina, et al.
Publicado: (2018)

Method development and validation of ursodiol and its major metabolites in human plasma by HPLC-tandem mass spectrometry
por: Pinto, Márcio Cardoso, et al.
Publicado: (2019)

Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis
por: Gantzel, Rasmus Hvidbjerg, et al.
Publicado: (2021)

Macrophage activation marker sCD163 correlates with accelerated lipolysis following LPS exposure: a human-randomised clinical trial
por: Rittig, Nikolaj, et al.
Publicado: (2017)

Liver cirrhosis, other liver diseases, and risk of hospitalisation for intracerebral haemorrhage: A Danish population-based case-control study
por: Grønbæk, Henning, et al.
Publicado: (2008)

The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson’s disease
por: Glavind, Emilie, et al.
Publicado: (2020)

Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Roux‐en‐Y gastric bypass
por: Kazankov, Konstantin, et al.
Publicado: (2022)

Effect of Combination Therapy with a Calcium Channel Blocker and an Angiotensin-Converting Enzyme Inhibitor on Renal Hypertrophy and Urinary Albumin Excretion in Diabetic Rats
por: Nielsen, Birgitte, et al.
Publicado: (2003)

Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis
por: Lleo, Ana, et al.
Publicado: (2016)

Development and validation of the Cirrhotic Ascites Severity model—A patient‐reported outcome‐based model to predict 1‐year mortality
por: Gantzel, Rasmus Hvidbjerg, et al.
Publicado: (2022)

Extrahepatic Manifestations of Primary Biliary Cholangitis
por: Chalifoux, Sara L, et al.
Publicado: (2017)

Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis
por: Sarcognato, Samantha, et al.
Publicado: (2021)

Antibody-Directed Glucocorticoid Targeting to CD163 in M2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes
por: Svendsen, Pia, et al.
Publicado: (2016)

Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension
por: Ørntoft, Nikolaj Worm, et al.
Publicado: (2021)

A nationwide study of autoimmune liver diseases in the Faroe Islands: Incidence, prevalence, and causes of death 2004 - 2021
por: Nielsen, Kári Rubek, et al.
Publicado: (2023)

Low Incidence of hepatic sinusoidal obstruction syndrome/veno-occlusive disease in adults undergoing allogenic stem cell transplantation with prophylactic ursodiol and low-dose heparin
por: Stutz, Lina, et al.
Publicado: (2022)

Highly Increased Levels of Inter-α-inhibitor Heavy Chain 4 (ITIH4) in Autoimmune Cholestatic Liver Diseases
por: Laursen, Tea Lund, et al.
Publicado: (2022)

Predicting Progression, Recurrence, and Survival in Pancreatic Neuroendocrine Tumors: A Single Center Analysis of 174 Patients
por: Krogh, Sara, et al.
Publicado: (2022)

P1723: A FEASIBILITY STUDY OF PEER SUPPORT IN FAMILY CAREGIVERS OF PATIENTS NEWLY DIAGNOSED WITH HEMATOLOGIC MALIGNANCY
por: Nielsen, I. H., et al.
Publicado: (2022)

Osteoporosis in primary biliary cholangitis
por: Danford, Christopher J, et al.
Publicado: (2018)

Baricitinib and primary biliary cholangitis
por: Gordon, Stuart C., et al.
Publicado: (2021)

Isolated congenital hepatic fibrosis associated with TMEM67 mutations: report of a new genotype–phenotype relationship
por: Vogel, Ida, et al.
Publicado: (2017)

Overlap Syndrome between Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
por: Sundaram, Sridhar, et al.
Publicado: (2018)

Effects and safety of natriuretic peptides as treatment of cirrhotic ascites: A systematic review and meta-analysis
por: Gantzel, Rasmus Hvidbjerg, et al.
Publicado: (2022)

New tight junction protein 2 variant causing progressive familial intrahepatic cholestasis type 4 in adults: A case report
por: Wei, Chun-Shan, et al.
Publicado: (2020)

Family caregiver ambassador support for caregivers of patients with newly diagnosed hematological cancer: a feasibility study
por: Husted Nielsen, Iben, et al.
Publicado: (2022)

Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis
por: Zimmermann-Nielsen, Erik, et al.
Publicado: (2005)

Transmembrane 163 (TMEM163) protein effluxes zinc
por: Sanchez, Vanessa B., et al.
Publicado: (2019)

Follicular T Helper Cell Signatures in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
por: Adam, Leonie, et al.
Publicado: (2018)

Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics
por: Park, Ji-Won, et al.
Publicado: (2022)

Visceral obesity is associated with increased soluble CD163 concentration in men with type 2 diabetes mellitus
por: Sørensen, Lars Peter, et al.
Publicado: (2015)

Evaluation of the United Kingdom‐primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population
por: Alomari, Mohammad, et al.
Publicado: (2019)

Obeticholic acid for primary biliary cholangitis
Publicado: (2020)

Current understanding of primary biliary cholangitis
por: Tanaka, Atsushi
Publicado: (2021)

Primary biliary cholangitis: pathogenic mechanisms
por: Prieto, Jesús, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ttnpmpm43qboa9lik3eutjvhe2